Bavarian Nordic A/S, which develops vaccines for cancer and infectious diseases, reported a large pick-up in third quarter revenue and said it will reach its full-year target of about DKK 500 million (€67.2 million). For the year, it expects a pretax loss of DKK 350 million.
